Alkem Laboratories to Acquire 51-55% Stake in Occlutech Holding AG for EUR 180.70 Million

Alkem Laboratories, through its wholly owned subsidiary Alkem Medtech Pvt Ltd, has offered to acquire at least 51% and up to 55% of the issued share capital of Occlutech Holding AG. The proposed acquisition is expected to be completed by 30th June, 2026, subject to customary conditions to closing. Occlutech is a Swiss limited liability company engaged in the business of developing, manufacturing, and marketing minimally invasive cardiac implants and accessories. The acquisition will enable Alkem Laboratories to enter the advanced cardiovascular devices business segment, with Occlutech's high-quality products and extensive distribution network.